London-based Perceptic, which says its end-to-end AI platform for drug development is being used by top pharmaceuticals, raised a $12M seed led by Accel (Jeremy Kahn/Fortune)
DGX agentJeremy Kahn / Fortune: London-based Perceptic, which says its end-to-end AI platform for drug development is being used by top pharmaceuticals, raised a $12M seed led by Accel — A trio of former Palan